EUVIMEDEUVIMED entdecken
Crossref

Association of CEA, NSE, CYFRA 21-1, SCC-Ag, and ProGRP with Clinicopathological Characteristics and Chemotherapeutic Outcomes of Lung Cancer

Huijuan Bi, Lina Yin, Wenhao Fang, Shenglan Song, Shan Wu, Jilu Shen

Laboratory Medicine · 2023

DOI: 10.1093/labmed/lmac122 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Laboratory Medicine, 2023. Verfasst von Huijuan Bi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, Anhui Public Health Clinical Center, The First Affiliated Hospital of Anhui Medical University North District, Hef…. Hauptthemen laut MEDLINE: Lung Neoplasms, Lung Diseases, Carcinoma, Squamous Cell. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: University Cooperation and Public Health Collaborative Innovation Project of Anhui Provincial Department of Education, Anhui Institute of Translational Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The aim of this study was to investigate the association of serum carcinoembryonic antigen (CEA), nerve-specific enolase (NSE), cytokeratin 19 fragment (CYFRA21-1), squamous cell carcinoma antigen (SCC-Ag), and pro-gastrin-releasing peptide (ProGRP) with the clinicopathological characteristics and chemotherapeutic outcomes of patients with lung cancer.

Methods

A total of 189 patients with lung cancer (lung cancer group) diagnosed at the Fourth Affiliated Hospital of Anhui Medical University from January 2020 to December 2021 were included. During the same period, 199 patients with benign lung disorders were included as the benign lung disease group and 75 healthy people were selected as the control group. The serum concentrations of CEA, NSE, CYFRA21-1, SCC-Ag, and ProGRP in all the 3 groups were analyzed and compared in patients with different lung cancer tumor-node-metastasis (TNM) stages and pathological classifications. A total of 11 patients with small cell lung cancer (SCLC) and 18 patients with lung adenocarcinoma (LAC) were further evaluated for the dynamic changes of CEA, NSE, CYFRA21-1, SCC-Ag, and ProGRP before chemotherapy and during the 6 courses of chemotherapy, and the outcome of chemotherapy was evaluated every 2 courses.

Results

The serum concentrations of CEA, NSE, CYFRA21-1, SCC-Ag, and ProGRP in the lung cancer group were significantly higher than those in the control group (P < .05). We found statistically significant differences in serum CEA, NSE, CYFRA 21-1, SCC-Ag, and ProGRP among patients with different pathological types (LAC, squamous cell carcinoma, or SCLC) and different stages (I–IV). The ProGRP and NSE had the highest expression in SCLC, CEA showed the highest expression in LAC, whereas CYFRA21-1 and SCC-Ag showed the highest expression in lung squamous cell carcinoma (LSCC). The concentrations of all the markers were elevated in the advanced pathological stages. The receiver operating characteristic curve analysis showed that the diagnostic value of the combined detection of CEA, NSE, CYFRA 21-1, SCC-Ag, and ProGRP for lung cancer was significantly higher than using a single biomarker (P < .05). Our dynamic monitoring results show that ProGRP progressively decreased in remission cases of SCLC and CEA progressively decreased in LAC remission cases.

Conclusion

CEA, NSE, CYFRA 21-1, SCC-Ag, and ProGRP have good clinical value in the early diagnosis, differential diagnosis, and progression monitoring of lung cancer. The ProGRP and CEA concentrations are beneficial for evaluating the outcome of chemotherapy in SCLC and LAC. The combined detection of multiple biomarkers shows improved clinical value in the early diagnosis of lung cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsLung DiseasesCarcinoma, Squamous CellHumansKeratin-19Carcinoembryonic AntigenBiomarkers, TumorAntigens, NeoplasmPhosphopyruvate HydrataseSerpinsPeptide FragmentsRecombinant Proteins

Stichwörter der Autor:innen

chemotherapycytokeratin 19 fragmentlung cancerneuron-specific enolasepro-gastrin-releasing peptidesquamous cell carcinoma antigen

Substanzen

Keratin-19Carcinoembryonic AntigenBiomarkers, TumorAntigens, NeoplasmPhosphopyruvate Hydratasesquamous cell carcinoma-related antigenSerpinsantigen CYFRA21.1pro-gastrin-releasing peptide (31-98)Peptide Fragments

Autor:innen und Institutionen

  • Department of Clinical Laboratory, Anhui Public Health Clinical Center, The First Affiliated Hospital of Anhui Medical University North District, Hefei, China.
  • Department of Oncology, Anhui Public Health Clinical Center, The First Affiliated Hospital of Anhui Medical University North District, Hefei, China.

Förderung

  • University Cooperation and Public Health Collaborative Innovation Project of Anhui Provincial Department of Education
  • Anhui Institute of Translational Medicine

Zitieren

APA

Bi, H., Yin, L., Fang, W., Song, S., Wu, S., & Shen, J. (2023). Association of CEA, NSE, CYFRA 21-1, SCC-Ag, and ProGRP with Clinicopathological Characteristics and Chemotherapeutic Outcomes of Lung Cancer. Laboratory Medicine. https://doi.org/10.1093/labmed/lmac122

Vancouver

Bi H, Yin L, Fang W, Song S, Wu S, Shen J. Association of CEA, NSE, CYFRA 21-1, SCC-Ag, and ProGRP with Clinicopathological Characteristics and Chemotherapeutic Outcomes of Lung Cancer. Laboratory Medicine. 2023. doi:10.1093/labmed/lmac122

BibTeX
@article{Bi2023,
  author = {Bi, Huijuan and Yin, Lina and Fang, Wenhao and Song, Shenglan and Wu, Shan and Shen, Jilu},
  title = {Association of CEA, NSE, CYFRA 21-1, SCC-Ag, and ProGRP with Clinicopathological Characteristics and Chemotherapeutic Outcomes of Lung Cancer},
  journal = {Laboratory Medicine},
  year = {2023},
  doi = {10.1093/labmed/lmac122}
}
Kostenlos starten →